https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Curr Opin Investig Drugs 2009 Jun;10(6):550-82009-06-01 00:00:002019-02-15 09:17:33Hyperthermia as an immunotherapy strategy for cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 Jun;17(3):821-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009 Jun;17(3):821-52009-06-01 00:00:002019-02-15 08:50:57[Dendritic cell-based immunotherapy for multiple myeloma — review]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Int. J. Oncol. 2009 Jun;34(6):1701-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Int. J. Oncol. 2009 Jun;34(6):1701-152009-06-01 00:00:002019-02-15 08:52:33Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Expert Opin Biol Ther 2009 Jun;9(6):677-88
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Expert Opin Biol Ther 2009 Jun;9(6):677-882009-06-01 00:00:002019-02-15 08:52:19Cellular immunotherapy for ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-01 / Oncol. Rep. 2009 Jun;21(6):1585-92
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-01 / Oncol. Rep. 2009 Jun;21(6):1585-922009-06-01 00:00:002019-02-15 08:53:21Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-29 / Arch. Immunol. Ther. Exp. (Warsz.) 2009 May-Jun;57(3):189-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-29 / Arch. Immunol. Ther. Exp. (Warsz.) 2009 May-Jun;57(3):189-982009-05-29 00:00:002019-02-15 08:44:13Dendritic cell-based cancer immunotherapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-27 / Cell. Immunol. 2009;259(1):13-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-27 / Cell. Immunol. 2009;259(1):13-202009-05-27 00:00:002020-01-08 10:10:17Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-14 / J. Theor. Biol. 2009 Aug;259(4):820-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-14 / J. Theor. Biol. 2009 Aug;259(4):820-72009-05-14 00:00:002019-02-15 08:44:16On immunotherapies and cancer vaccination protocols: a mathematical modelling approach
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-14 / Cancer Sci. 2009 Aug;100(8):1502-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-14 / Cancer Sci. 2009 Aug;100(8):1502-92009-05-14 00:00:002019-02-15 08:52:02Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-07 / J. Clin. Immunol. 2009 Sep;29(5):657-642009-05-07 00:00:002019-02-15 08:49:27Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy
